
3-Phenoxybenzoic acid | CAS:3739-38-6
3-Phenoxybenzoic acid
- 名称:3-苯氧基苯甲酸; 间苯氧基苯甲酸 | 3-Phenoxybenzoic acid
- CAS号:3739-38-6
- 别名:
- 分子式:C13H10O3
- 分子量:214.22
- EINESC号:223-121-2
产品描述
物理化学性质
熔点 | 147-150 ºC |
---|
安全数据
危险品标志 | Xi |
---|---|
危险类别码 | R36/37/38 |
安全说明书 | S26;S37/39 |
产品合成路线
名称 | CAS号 |
---|
更多
文章
同行评议文献
Nutraceuticals in the management of osteoarthritis.James J Clayton Orthopedics, 30(8), 624-629 (2007-08-31)
[Leg ulcers caused by prolidase deficiency].G Pasolini et al.Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 123(10), 493-496 (1988-10-01)
Oxaceprol, an atypical inhibitor of inflammation and joint damage.M Ionac et al.Pharmacological research, 33(6), 367-373 (1996-06-01)
Antirheumatic agents and leukocyte recruitment. New light on the mechanism of action of oxaceprol.M J Parnham Biochemical pharmacology, 58(2), 209-215 (1999-07-28)
Effects of oxaceprol on the microcirculation in ischemia/reperfusion injury.A Harris et al.European journal of medical research, 3(4), 182-188 (1998-05-16)
[Assessment of the placebo effect of symptomatic slow-acting anti-arthritics].P Villani et al.Presse medicale (Paris, France : 1983), 27(5), 211-214 (1998-10-13)
Oxaceprol is a well-tolerated therapy for osteoarthritis with efficacy equivalent to diclofenac.G Herrmann et al.Clinical rheumatology, 19(2), 99-104 (2000-05-03)
Pharmacokinetics and metabolism of 14C-oxaceprol in beagle dogs after intramuscular and oral administration.G Lachmann et al.Arzneimittel-Forschung, 40(2 Pt 1), 200-206 (1990-02-01)
[Oxaceprol reduced leukocyte adhesion and extravasation and preserves perfusion of tissue after ischemia/reperfusion].A G Harris et al.Langenbecks Archiv fur Chirurgie. Supplement. Kongressband. Deutsche Gesellschaft fur Chirurgie. Kongress, 115(Suppl I), 447-451 (2003-10-02)
Oxaceprol--a randomised, placebo-controlled clinical study in osteoarthritis with a non-conventional non-steroidal anti-inflammatory drug.K Krüger et al.Clinical and experimental rheumatology, 25(1), 29-34 (2007-04-10)
Versatile whole-organ/body staining and imaging based on electrolyte-gel properties of biological tissues.Etsuo A Susaki et al.Nature communications, 11(1), 1982-1982 (2020-04-29)
Prolidase deficiency with iminodipeptiduria: biochemical investigations and first results of attempted therapy.C Charpentier et al.Journal of inherited metabolic disease, 4(2), 77-78 (1981-01-01)
Oxaceprol is as effective as diclofenac in the therapy of osteoarthritis of the knee and hip.H W Bauer et al.Clinical rheumatology, 18(1), 4-9 (1999-03-24)
Structure-guided design and optimization of small molecules targeting the protein?protein interaction between the von Hippel?Lindau (VHL) E3 ubiquitin ligase and the hypoxia inducible factor (HIF) alpha subunit with in vitro nanomolar affinities.Galdeano C, et al. Journal of Medicinal Chemistry, 57(20), 8657-8663 (2014)
[The interaction of oxaceprol and fluindione].B Bannwarth et al.Therapie, 45(2), 162-163 (1990-03-01)
Adenosine postsynaptically modulates supraoptic neuronal excitability.Todd A Ponzio et al.Journal of neurophysiology, 93(1), 535-547 (2004-09-10)
Synthesis and characterization of a novel biodegradable polymer poly (lactic acid?glycolic acid?4?hydroxyproline).Duan J, et al. Journal of Applied Polymer Science, 103(6), 3585-3590 (2007)
Evaluation of various tissue-clearing techniques for the three-dimensional visualization of liposome distribution in mouse lungs at the alveolar scale.Kohei Togami et al.International journal of pharmaceutics, 562, 218-227 (2019-03-25)
Stereospecific syntheses of all four stereoisomers of 4-fluoroglutamic acid.Hudlicky M. Journal of Fluorine Chemistry, 60(2-3), 193-210 (1993)
Oxaceprol, an atypical inhibitor of inflammation, reduces leukocyte adherence in mouse antigen-induced arthritis.A Veihelmann et al.Acta orthopaedica Scandinavica, 72(3), 293-298 (2001-08-02)
[Effect of oxaceprol on the structure of proteoglycans synthesized by articular chondrocytes from calves].H Riera et al.Revue du rhumatisme et des maladies osteo-articulaires, 58(9), 629-634 (1991-10-01)
Quantum mechanical and NMR studies of ring puckering and cis/trans-rotameric interconversion in prolines and hydroxyprolines.Abil E Aliev et al.The journal of physical chemistry. A, 113(40), 10858-10865 (2009-09-18)
[Sclerodermiform porphyria cutanea tarda. Ultrastructural study].J Ocaña et al.Medicina cutanea ibero-latino-americana, 13(2), 157-166 (1985-01-01)
Production of N-acetyl cis-4-hydroxy-L-proline by the yeast N-acetyltransferase Mpr1.Bach Thi Mai Hoa et al.Journal of bioscience and bioengineering, 114(2), 160-165 (2012-05-15)
Pseudopoly (amino acids): A Study of the Synthesis and Characterization of Poly (trans-4-hydroxy-N-acyl-L-proline esters).Kwon H Y and Langer R Macromolecules, 22(8), 3250-3255 (1989)
[Meta-analysis of the efficacy of adenosylmethionine and oxaceprol in the treatment of osteoarthritis].S Witte et al.Der Orthopade, 31(11), 1058-1065 (2002-11-19)
Cellular and Molecular Probing of Intact Human Organs.Shan Zhao et al.Cell, 180(4), 796-812 (2020-02-16)
[Autoradiography studies of the effect of oxaceprol on the metabolism of joint cartilage in vitro and in vivo].D A Kalbhen et al.Zeitschrift fur Rheumatologie, 46(3), 136-142 (1987-05-01)
[Effect of oxaceprol on the synthesis and degradation in vitro of proteoglycans and proteins by calf articular cartilage explants].H Riera et al.Revue du rhumatisme et des maladies osteo-articulaires, 57(7-8), 579-583 (1990-07-01)
Determination of oxaceprol in rat plasma by LC-MS/MS and its application in a pharmacokinetic study.Jifeng Gu et al.Journal of pharmaceutical and biomedical analysis, 54(1), 173-178 (2010-09-14)
[Action of N-acetyl-hydroxyproline in the treatment of cutaneous ulcerative lesions].C Famulari et al.Annali italiani di chirurgia, 51(5), 527-536 (1979-01-01)
Microbial production of N-acetyl cis-4-hydroxy-L-proline by coexpression of the Rhizobium L-proline cis-4-hydroxylase and the yeast N-acetyltransferase Mpr1.Thi Mai Hoa Bach et al.Applied microbiology and biotechnology, 97(1), 247-257 (2012-06-19)
备注
Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271 +A13(1).
名称 | CAS号 |
---|

相关产品
相关资讯
问
热门标签
询 单
请 填 写 相 关 信 息
- 请填写产品名称!
- CAS号
- 请正确填写公司名称!
- 请正确填写联系人!
- 请正确填写联系电话!
- 请正确填写联系邮箱!
- 请描述您的问题!